Trial Profile
Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 31 Mar 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2022 Results of an analysis of data from real world and NCT02827617 study assessed the role of autonomous BCR signaling on constitutive VLA-4 activation state in CLL presented at the 27th Congress of the European Haematology Association